Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014, with the announcement issued on June 11, 2014. The filing reports positive clinical data from two Phase III studies conducted in collaboration with Theravance, Inc. The studies evaluated the efficacy and safety of adding Incruse Ellipta (umeclidinium) to Relvar/Breo Ellipta (fluticasone furoate/vilanterol) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical data announcement rather than a financial report.
Material Changes and Clinical Results
The primary material change reported is the successful outcome of two 12-week, multicentre, randomised, double-blind, placebo-controlled studies (200109 and 200110) involving 1,238 COPD patients. Key findings include:
- Lung Function Improvement: Adding umeclidinium (UMEC) 62.5mcg or 125mcg to FF/VI resulted in statistically significant improvements in trough FEV1 at Day 85 compared to placebo plus FF/VI.
- Study 200109 Results: UMEC 62.5mcg showed a 124mL difference; UMEC 125mcg showed a 128mL difference versus placebo (both p<0.001).
- Study 200110 Results: UMEC 62.5mcg showed a 122mL difference; UMEC 125mcg showed a 111mL difference versus placebo (both p<0.001).
- Safety Profile: Adverse event incidence was comparable across treatment groups (ranging from 30% to 39%). Common adverse events included headache, nasopharyngitis, and back pain. Cardiovascular adverse events of special interest were low (1-3%).
- Mortality: Deaths were reported in placebo groups and one UMEC treatment group but were deemed non-drug related by investigators.
Guidance, Outlook, and Risks
Management Commentary: GSK and Theravance executives stated that these data strengthen the evidence base for Incruse and provide physicians with a potential triple therapy approach for COPD. The companies intend to continue research to expand understanding of combined medicine use.
Regulatory Status: Incruse Ellipta (62.5mcg) is approved in the US, Canada, and Europe. The 125mcg dose used in the study is not currently approved anywhere. Full results will be posted to clinicaltrials.gov and presented at a future scientific meeting.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding risks that could cause actual results to differ from projections. Specific product risks noted include:
- Incruse Ellipta: Contraindicated in patients with severe hypersensitivity to milk proteins; caution advised for narrow-angle glaucoma and urinary retention.
- Breo/Relvar Ellipta: Contains a LABA which carries a risk of asthma-related death (class effect); increased incidence of pneumonia observed in COPD trials; risk of adrenal suppression and bone mineral density decreases.
Investor Verification Checklist
- Verify the regulatory approval status of the 125mcg umeclidinium dose, which was tested but is not currently approved.
- Confirm the timeline for the submission of regulatory applications for the triple therapy combination (Incruse + Relvar/Breo).
- Review the full safety data regarding pneumonia incidence and cardiovascular events in the upcoming clinicaltrials.gov posting.
- Assess the commercial impact of triple therapy on the existing respiratory portfolio revenue streams.
- Monitor Theravance's potential royalty revenue implications based on the success of the combination therapy.